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Objective. Pain is a significant burden for patients with rheumatoid arthritis (RA) despite advancements in 
treatment. We undertook this study to examine the independent contribution of pain centralization to the pain 
experience of patients with active RA.
Methods. A total of 263 RA patients with active disease underwent quantitative sensory testing (QST), including 
assessment of extraarticular pressure pain thresholds (PPTs), temporal summation (TS), and conditioned pain 
modulation (CPM). The pain experience was assessed by a pain intensity numeric rating scale and the Patient- 
Reported Outcomes Measurement Information System pain interference computerized adaptive test. We examined 
associations between QST measures and pain intensity and pain interference. Multiple linear regression models were 
adjusted for demographic and clinical variables, including swollen joint count and C- reactive protein level.
Results. Patients with the lowest PPTs (most central dysregulation) reported higher pain intensity than patients 
with the highest PPTs (adjusted mean difference 1.02 [95% confidence interval (95% CI) 0.37, 1.67]). Patients with 
the highest TS (most central dysregulation) had higher pain intensity than those with the lowest TS (adjusted mean 
difference 1.19 [95% CI 0.54, 1.84]). CPM was not associated with differences in pain intensity. PPT and TS were 
not associated with pain interference. Patients with the lowest CPM (most centrally dysregulated) had lower pain 
interference than patients with the highest CPM (adjusted mean difference –2.35 [95% CI –4.25, –0.44]).
Conclusion. Pain centralization, manifested by low PPTs and high TS, was associated with more intense pain. 
Clinicians should consider pain centralization as a contributor to pain intensity, independent of inflammation.
INTRODUCTION
Pain is a prevalent symptom in patients with rheumatoid 
arthritis (RA) and is a high patient priority for improvement in care 
(1,2). While significant advancements have been made in the 
treatment of RA, pain continues to be a significant burden (3). 
Thus, a more complete understanding of the mechanisms under-
lying pain in RA is needed.
Pain in RA has been classically understood as a conse-
quence of inflammation acting on peripheral nociceptors. However, 
recent observations have expanded the understanding of pain in 
RA to include a role for central nervous system (CNS) modulation 
of pain perception, termed “pain centralization” (4–7). For instance, 
the proinflammatory cytokines tumor necrosis factor and interleu-
kin- 6 have been shown in animal models to directly act on spinal 
cord neurons, eliciting development of spinal hyperexcitability to 
pain. In some cases, this hyperexcitability persists despite neutral-
ization of inflammation (8–11). Similarly, in patients with RA, pain 
often persists despite objective evidence of improvement in inflam-
mation demonstrated by normalization of inflammatory markers 
and reduced swollen joint counts (12,13). Increased sensitivity to 
pain in regions distant from joints has also been noted, providing 
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further support for the role of pain centralization in RA (14). Greater 
understanding of the role of pain centralization in RA is needed 
because patients with pain driven predominantly by pain cen-
tralization may be treated better by centrally acting agents (e.g., 
serotonin norepinephrine reuptake inhibitors and gabapentinoids) 
or cognitive behavioral therapy rather than changes in or esca-
lation of treatment with disease- modifying antirheumatic drugs 
(DMARDs).
Quantitative sensory testing (QST) is a semiquantita-
tive method that can detect abnormalities in pain processing. 
Three commonly used QST methodologies include pressure pain 
thresholds (PPTs), temporal summation (TS), and conditioned 
pain modulation (CPM). Decreased PPTs at swollen joints indi-
cate increased pain sensitivity as a consequence of local inflam-
mation, while decreased PPTs at nonarticular sites are thought 
to be indicative of pain centralization (15,16). Abnormal TS rep-
resents increased responsiveness of the dorsal horn neurons to 
peripheral stimulation, which is a specific mechanism of pain cen-
tralization (17). An additional mechanism of pain centralization is 
decreased activity of the descending analgesic pathways, which 
can be assessed by the CPM paradigm (18). We hypothesized 
that central dysregulation of pain processing, manifested by low 
extraarticular PPT, exaggerated TS, and blunted CPM, would be 
associated with patient- reported measures of pain in patients 
with active RA and that this association would be independent of 
inflammatory activity.
PATIENTS AND METHODS
Study population. The Central Pain in Rheumatoid Arthritis 
study is an observational, multicenter study designed to examine 
the relationship between QST- assessed pain mechanisms and 
patient- reported measures of pain experience in patients with 
active RA undergoing initiation or change in DMARD therapy (19). 
A total of 295 subjects from 5 US academic medical centers were 
recruited from January 2014 through June 2017.
Participants meeting the following criteria were included for 
the study: a diagnosis of RA based on the American College of 
Rheumatology/European League Against Rheumatism 2010 clas-
sification criteria; active disease that necessitates initiation of or 
change in treatment with DMARDs; and the ability to participate in 
a baseline study visit prior to the change in or initiation of DMARDs 
(20). Subjects were excluded for the following reasons: peripheral 
neuropathy; peripheral vascular disease resulting in severe claudi-
cation or rest pain; Raynaud’s phenomenon; chronic opioid use; 
changing dose of a centrally acting pain medication (e.g., amitrip-
tyline, duloxetine, milnacipran, gabapentin, or pregabalin) within 
3 months of study enrollment; or glucocorticoid use equivalent to 
>10 mg daily of prednisone.
QST. QST was performed as previously described (21). All 
assessors underwent a 1- day training session to ensure stan-
dardization of QST procedures across sites. We calculated a two- 
way, mixed, single- score, intraclass correlation coefficient (ICC) 
(1,3) to assess reproducibility of QST between assessors (22). 
According to Cicchetti et al, an ICC from 0.4 to 0.59 was con-
sidered fair, 0.6 to 0.74 was considered good, and 0.75 to 1 was 
considered excellent (23). ICCs ranged from 0.71 to 0.9 for PPTs 
and TS, whereas the ICC for CPM was 0.45 (19).
PPTs. A Force Ten FDX algometer (Wagner Instruments) 
was used to determine extraarticular PPTs at the bilateral trape-
zius muscles. The algometer probe was placed on the center of 
the trapezius muscle. Pressure on the algometer was increased 
at a rate of 0.5 kgf/second until pain was reported. Three trials 
were performed at each trapezius muscle. The mean PPT was 
determined by averaging the 3 trials on both sides. We chose 
the trapezius as the primary site to evaluate pain centralization 
for the following reasons: 1) the trapezius is a commonly used 
site for assessment of PPTs in the pain literature; 2) the litera-
ture supports standard values for PPT at the trapezius in normal 
adults; and 3) the trapezius is a site distant from joints commonly 
affected by RA, enabling assessment of pain centralization with-
out the confounding effects of peripheral sensitization due to ac-
tive joint inflammation (24–27).
TS. TS was assessed at the dorsal forearm using 6 calibrat-
ed probes of increasing weight. The probes were tested on the 
subject’s forearm using sequentially increasing weight until the 
patient reported a pain level of 30–40 on a 100- point scale. We 
used the probe that generated a pain score of 30–40 for further 
testing. The probe was tapped 10 times with each tap lasting 
0.5 seconds with a 1- second interval between taps. The subject 
rated the pain produced by the probe at taps 1, 5, and 10. TS 
was determined by subtracting the pain rating for tap 1 from the 
pain rating for tap 10. We repeated the test 3 times. The mean 
TS was calculated as the average of the 3 trials. We divided the 
resulting value by 10 to normalize TS to the units used in the 
standard pain scale. Higher TS was considered to be indicative 
of central sensitization. As with PPT, we chose the dorsal fore-
arm due to its distance from articular sites to avoid confounding 
from peripheral sensitization.
SIGNIFICANCE & INNOVATIONS
• This is the first multicenter study to determine the 
association between pain centralization (assessed 
by pressure pain thresholds, temporal summation, 
and conditioned pain modulation) and patient- 
reported pain in patients with active rheumatoid 
arthritis (RA) necessitating change in therapy.
• Pain centralization is associated with increased 
 patient-reported pain, independent of inflammation.
• Clinicians should consider pain centralization as a 
contributor to patient-reported pain when tailoring 
individualized therapy for patients with RA.
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CPM. CPM was assessed using a conditioning stimulus 
(a painful stimulus that activates the descending analgesic pain 
pathways) and a test stimulus (a painful stimulus used to assess 
pain sensitivity). The conditioning procedure involved placing 
the subject’s right hand in a cold water bath between 5°C and 
7°C. The test stimulus was produced by placing an algometer 
probe at the center of the left trapezius muscle (contralateral to 
the hand placed in the cold water bath) and applying a force of 
0.5 kgf/second until pain was reported by the participant. PPT 
was measured immediately prior to cold bath immersion. PPT 
was again assessed at 20 seconds of cold bath immersion or 
immediately after removal of the hand if pain was intolerable 
before the 20 seconds had passed. CPM was calculated as 
the ratio of the second PPT to the first PPT. Values >1 represent 
efficient CPM, whereas values <1 represent inefficient CPM.
Clinical variables. We assessed the subjects’ pain expe-
rience using Patient- Reported Outcomes Measurement Informa-
tion System (PROMIS) questionnaires. The PROMIS global health 
short form was administered, while pain interference, depression, 
anxiety, and sleep disturbance were assessed using computer-
ized adaptive testing (CAT) (28–31). PROMIS sleep disturbance 
was stratified into categories of none, mild, and moderate/severe 
(32). Clinical variables were age, sex, race, educational status, RA 
duration, and body mass index (BMI). Blood serum was analyzed 
for C- reactive protein (CRP), rheumatoid factor (RF), and anti–
citrullinated protein antibody at a single laboratory. A standard-
ized joint count (28 swollen joints) was obtained by trained study 
staff members. Comorbidity was assessed using a modified 
Charlson comorbidity index score (33).
Statistical analysis. The primary outcome was overall pain 
intensity assessed on a 0–10 numeric rating scale (item Global07 
on the PROMIS global health short form). The secondary out-
come was the PROMIS pain interference CAT score. Pain interfer-
ence measures the extent to which pain interferes with patients’ 
physical, mental, and social activities (30). The primary predictor 
was the PPT at the trapezius muscle. Secondary predictors were 
TS and CPM. To avoid assumptions of linearity and to address 
differences in PPT responses between men and women, the 
QST measures were categorized by sex- specific tertiles. For ease 
of interpretation, the tertiles are presented by degree of central dys-
regulation (least, moderate, and most). More central dysregulation 
corresponded to decreasing PPT and CPM tertiles (T3, T2, T1) 
and increasing TS tertiles (T1, T2, T3).
Standard covariates included age, sex, race, and BMI. Educa-
tion level, anxiety, and sleep disturbance were included as covar-
iates due to their association with pain based on literature review 
(26,34,35). We included seropositivity (RF and/or citrullinated pep-
tide positive), disease duration, and the modified Charlson comor-
bidity index score as covariates per clinical experience. Swollen joint 
count (SJC) and CRP level were included as covariates because 
our objective was to assess the role of pain centralization on pain 
experience independent of inflammation. Finally, we included a 
site variable to account for potential differences between patient 
populations across study sites. These variables were included in 
all statistical models. The relationship between QST tertiles and 
patient- reported pain outcomes was evaluated using multiple linear 
regression. All analyses were performed using SAS, version 9.4.
RESULTS
Clinical characteristics. This study sample of 263 patients 
with RA had a mean age of 57.4 years (range 18–81 years) and 
included primarily white (75%) and female (82%) patients with 
an average RA disease duration of 9.8 years (Table 1). Another 
33 patients from the parent study did not contribute to these 
analyses due to missing data (4 with missing outcome data, 11 
with missing predictor data, and 18 with missing covariate data). 
These patients were similar to those in the study sample with 
the exception of statistically significant differences in education 
(75.7% with some college or higher in the included sample versus 
48.5% in the excluded sample), anxiety (mean PROMIS T score 
of 53.6 in the included sample versus 57.5 in the excluded sam-
ple), and sleep disturbance (25.1% with moderate/severe sleep 
disturbance in the included sample versus 43.3% with moderate/
severe sleep disturbance in the excluded sample).
Patient- reported pain measures by QST tertile. The 
unadjusted mean pain intensity and pain interference scores 
for each QST tertile group are summarized in Tables 2–4. With 
increasing central dysregulation as defined by PPT, mean scores 
Table 1. Clinical characteristics of the subjects (n = 263 patients)*
Characteristic Value
Age, years 54.7 ± 13.8
Female sex, % 81.8
White race, % 74.9
BMI, kg/m2 28.6 ± 6.8
Some college or higher, % 75.7
Seropositive, % 73.0
Disease duration, years 9.8 ± 11.9
CRP, mg/liter 7.9 ± 12.2
SJC 5.1 ± 5.0
PROMIS depression score 50.9 ± 9.1
PROMIS anxiety score 53.6 ± 8.9




Modified Charlson comorbidity index score 1.3 ± 1.1
DAS28 score 3.8 ± 1.1
CDAI score 23.7 ± 13.9
* Values are the mean ± SD unless indicated otherwise. BMI = body 
mass index; CRP = C- reactive protein; SJC = swollen joint count; 
PROMIS = Patient- Reported Outcomes Measurement Information 
System; DAS28 = Disease Activity Score in 28 joints; CDAI = Clinical 
Disease Activity Index. 
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increased for both pain intensity (least: 4.51, moderate: 5.11, 
and most: 5.95) and pain interference (least: 58.66, moderate: 
60.32, and most: 62.13). Similarly, with increasing central dysreg-
ulation as defined by TS, mean scores increased for both pain 
intensity (least: 4.24, moderate: 5.55, and most: 5.71) and pain 
interference (least: 58.58, moderate 60.69, and most: 61.79). 
However, as central dysregulation defined by CPM increased, no 
trend was observed in pain intensity or pain interference.
Associations between QST tertile and measures of 
patient- reported pain. Trapezius PPTs. In both unadjust-
ed and adjusted analyses, greater central pain dysregulation, 
assessed by trapezius PPT, was significantly associated with 
higher pain intensity (P ≤ 0.002 for trend) (Table 5). Compared 
to the least dysregulated group (highest tertile of PPT), mean 
pain intensity was 0.48 points higher in the group with moder-
ate central dysregulation (middle tertile of PPT) and 1.02 points 
higher in the group with the most central dysregulation (lowest 
tertile of PPT) in adjusted analyses. Covariates in the PPT mod-
el associated with greater pain intensity included sleep distur-
bance and less education. Greater central pain dysregulation 
was also significantly associated with more pain interference in 
unadjusted analyses (P for trend = 0.001). However, the trend 
was attenuated in the adjusted analysis (P for trend = 0.066). 
In addition, sleep disturbance, anxiety, and CRP level were all 
significantly associated with greater pain interference in the 
PPT model.
TS. In both unadjusted and adjusted analyses, greater cen-
tral pain dysregulation, assessed by TS, was significantly asso-
ciated with higher pain intensity (P < 0.001 for trend)  (Table 5). 
Compared to the least dysregulated group (lowest tertile of 
TS), mean pain intensity was 0.96 points higher in the group 
with moderate central dysregulation (middle tertile of TS) and 
1.19 points higher in the group with the most central dysregula-
tion (highest tertile of TS) in adjusted analyses. Covariates in the 
TS model associated with greater pain intensity included sleep 
disturbance and less education. Greater central pain dysregula-
tion was also significantly associated with more pain interference 
in unadjusted analyses (P = 0.004 for trend). However, the trend 
was attenuated in the adjusted analysis (P = 0.205 for trend). In 
addition, sleep disturbance, anxiety, CRP level, and less educa-
tion were all significantly associated with greater pain interfer-
ence in the TS model.
CPM. CPM was not associated with pain intensity in 
unadjusted analyses or after adjusting for covariates, nor 
was a trend observed. Only sleep disturbance and less ed-
ucation were significantly associated with pain intensity in the 
CPM model. However, lower CPM, thought to be indicative of 
greater central pain dysregulation, was significantly associated 
with lower pain interference in adjusted analyses (P = 0.016 
for trend). Compared to the least dysregulated group (highest 
tertile of CPM), mean pain interference was 1.18 points lower 
in the group with moderate central dysregulation (middle tertile 
of CPM) and 2.35 points lower in the group with the most cen-
tral dysregulation (lowest tertile of CPM). Sleep disturbance, 
anxiety, CRP level, and white race were also associated with 
greater pain interference.
DISCUSSION
This study implicates pain centralization as a contributor 
to pain in patients with RA independent of the effects of inflam-
mation. Specifically, we observed an association between low 
extraarticular PPTs and high TS with pain intensity, which  persisted 
Table 2. Pain measures by PPT trapezius tertile, n = 263 patients*
Least central dysregulation 
(PPT tertile 3; n = 90)
Moderate central dysregulation 
(PPT tertile 2; n = 90)
Most central dysregulation 
(PPT tertile 1; n = 83)
PPT trapezius, 
kgf/second
4.62 ± 1.58 2.70 ± 0.69 1.48 ± 0.57
Pain intensity 
(NRS 0–10)
4.51 ± 2.38 5.11 ± 2.17 5.95 ± 2.08
Pain interference, 
T score
58.66 ± 8.05 60.32 ± 6.53 62.13 ± 6.32
* Values are the mean ± SD. PPT = pressure pain threshold; NRS = Numeric Rating Scale. 
Table 3. Pain measures by TS tertile, n = 263 patients*
Least central dysregulation 
(TS tertile 1; n = 85)
Moderate central dysregulation 
(TS tertile 2; n = 102)
Most central dysregulation 
(TS tertile 3; n = 76)
TS (range 0–100) 0.11 ± 2.68 8.78 ± 4.64 31.37 ± 12.82
Pain intensity 
(NRS 0–10)
4.24 ± 2.12 5.55 ± 2.34 5.71 ± 2.09
Pain interference, 
T score
58.58 ± 7.41 60.69 ± 6.99 61.79 ± 6.72
* Values are the mean ± SD. TS = temporal summation; NRS = Numeric Rating Scale. 
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after adjustment for CRP level and SJC. We additionally assessed 
aberrant descending pain modulation manifested by abnor-
mal CPM but did not find consistent evidence of an association 
between CPM and increased pain.
Low PPTs at extraarticular sites are thought to represent 
pain centralization (15). Fischer et al established normal values for 
PPTs at the trapezius in a study of 50 healthy volunteers (24). In 
comparison, our population of patients with active RA had lower 
PPTs at the trapezius, which is consistent with other studies 
showing lower extraarticular PPTs in patients with RA compared 
to healthy control subjects (36). For instance, Gerecz- Simon et al 
compared PPTs at multiple sites in healthy control subjects and 
patients with RA, osteoarthritis, and ankylosing spondylitis and 
noted the lowest PPTs in RA patients (37). Löfgren et  al noted 
similar results in a study showing lower PPTs in 45 patients with 
RA compared to 20 healthy control subjects (38).
To our knowledge, only 1 study has examined the associa-
tion between PPTs and pain in RA. Joharatnam et al reported an 
association between PPTs at the medial knee, tibia, and sternum 
with pain measured by the McGill Pain Questionnaire in a popu-
lation of 50 patients with RA, but this study did not account for 
potential confounding from inflammatory activity (39). Our study 
Table 4. Pain measures by CPM tertile, n = 263 patients*
Least central dysregulation 
(CPM tertile 3; n = 84)
Moderate central dysregulation 
(CPM tertile 2; n = 99)
Most central dysregulation 
(CPM tertile 1; n = 80)
CPM 1.79 ± 0.36 1.31 ± 0.07 1.10 ± 0.10
Pain intensity  
(NRS 0–10)
5.21 ± 2.27 4.86 ± 2.24 5.51 ± 2.33
Pain interference,  
T score
61.89 ± 7.40 59.93 ± 7.21 59.18 ± 6.57
* Values are the mean ± SD. CPM = conditioned pain modulation; NRS = Numeric Rating Scale. 
Table 5. Regression results for the association between quantitative sensory testing parameters and 
pain (n = 263 patients)*








Unadjusted 0.60 (–0.05, 1.25) 1.44 (0.78, 2.11)¶ <0.001¶
Adjusted# 0.48 (–0.15, 1.11) 1.02 (0.37, 1.67)¶ 0.002¶
TS
Unadjusted 1.31 (0.68, 1.95)¶ 1.48 (0.79, 2.16)¶ <0.001¶
Adjusted# 0.96 (0.36, 1.56)¶ 1.19 (0.54, 1.84)¶ <0.001¶
CPM
Unadjusted –0.36 (–1.02, 0.31) 0.30 (–0.40, 1.00) 0.420
Adjusted# –0.14 (–0.75, 0.47) 0.37 (–0.27, 1.01) 0.251
Pain interference outcome
PPT trapezius
Unadjusted 1.66 (–0.40, 3.72) 3.48 (1.37, 5.58)¶ 0.001¶
Adjusted# 1.11 (–0.79, 3.02) 1.84 (–0.12, 3.80) 0.066
TS
Unadjusted 2.12 (0.08, 4.16)¶ 3.21 (1.02, 5.40)¶ 0.004¶
Adjusted# 0.49 (–1.36, 2.35) 1.29 (–0.71, 3.28) 0.205
CPM
Unadjusted –1.96 (–4.03, 0.11) –2.71 (–4.89, –0.53)¶ 0.014¶
Adjusted# –1.18 (–3.00, 0.64) –2.35 (–4.25, –0.44)¶ 0.016¶
* Values are the mean difference (95% confidence interval). PPT = pressure pain threshold; TS = temporal 
summation; CPM = conditioned pain modulation. 
† Least central dysregulation is the reference. 
‡ Values represent the mean pain intensity/interference difference between the moderate central 
dysregulation group and the least central dysregulation group. 
§ Values represent the mean pain intensity/interference difference between the most central 
dysregulation group and the least central dysregulation group. 
¶ Significant. 
# Adjusted models used the following covariates: age, sex, race, education level, seropositivity 
(rheumatoid factor and/or anti–citrullinated peptide positive), disease duration, swollen joint count, 
C- reactive protein level, body mass index, depression, anxiety, sleep disturbance, modified Charlson 
comorbidity index score, and site. 
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confirms this association and adds to this finding by showing that 
this relationship persists after adjusting for multiple clinical var-
iables, including SJC and CRP level.
To evaluate the clinical implications of the association 
between PPTs and pain intensity, we considered the minimum 
clinically important difference (MCID) in pain intensity. Salaffi et al 
reported an MCID for pain intensity of 1 on a 0–10 numeric rat-
ing scale in a study of 825 patients with RA (n = 290) and other 
chronic musculoskeletal conditions, including osteoarthritis and 
ankylosing spondylitis (40). In our study, we report an adjusted 
difference in pain intensity of 1.02 between the most and least 
centrally dysregulated PPT groups, which is above the MCID, indi-
cating that this change is of clinical importance.
We also examined the relationship between PPTs and pain 
interference. In adjusted analyses, we observed a 1.84- point 
higher pain interference T score in the most centrally dysregulated 
PPT group compared to the least dysregulated group, which was 
not statistically significant. To provide clinical context, Chen et al 
established that the minimum important difference (MID), a mea-
sure similar to the MCID, in the PROMIS pain interference T score 
is between 2 and 3 (41).
To further clarify the mechanism of pain centralization in RA, 
we investigated a relationship between TS and pain. TS is thought 
to represent central sensitization due to increased responsiveness 
of the second order neurons of the dorsal horn of the spinal cord. 
Increased TS has been implicated as a specific mechanism of 
pain centralization in the prototypical central pain disorder, fibro-
myalgia (42). Higher TS was observed by Hermans et  al in 11 
patients with RA compared to 20 healthy control subjects (27). 
Additionally, Vladimirova et al noted greater TS in 38 RA patients 
with active disease compared to 38 healthy female control sub-
jects (43).
Our study is the first to report an association between TS and 
patient- reported pain in RA. In adjusted analyses, we show a higher 
pain intensity of 1.19 points on a scale of 0–10 in the most centrally 
dysregulated TS group compared to the least dysregulated group. 
Again, this increase is above the MCID for pain intensity in patients 
with RA. For pain interference, we noted a 1.29- point higher T score 
in the most centrally dysregulated group compared to the least cen-
trally dysregulated group, which was not statistically significant nor 
clinically important based on an MID of 2–3.
In addition to TS, we studied CPM as a potential mecha-
nism of pain regulation in active RA. The CPM paradigm involves 
the use of a conditioning stimulus to activate the descending 
analgesic pathways (44). We previously showed that patients 
with RA have lower CPM than pain- free control subjects, which 
is indicative of abnormalities in the descending analgesic path-
ways (26). However, in the current study, we found no asso-
ciation between CPM and pain intensity. When examining the 
association between CPM and pain interference, we noted that 
the group with greatest central dysregulation (manifested by the 
lowest CPM) had a lower average pain interference T score of 
2.35 points compared to the group with least central dysreg-
ulation. These results were unexpected given that dysregula-
tion of the CNS pain regulatory pathways would be expected 
to enhance pain intensity and pain interference. The absence 
of association between CPM and pain intensity suggests that 
dysfunction of the descending analgesic pathway may not be 
implicated in the pathogenesis of pain in RA or that CPM may 
be a poor measure of the descending analgesic pathway in 
some settings. For example, in patients with preexisting clinical 
pain, the descending analgesic pathways may already be acti-
vated, complicating the experimental assessment of pain using 
the CPM paradigm (45). Finally, of the QST measures used in 
this study, CPM was the least reproducible, and heterogeneity 
in measurement may have impacted our results.
Analysis of the correlation between the covariates in our model 
and pain is notable for additional findings. First, moderate- to- 
severe sleep disturbance was significantly associated with pain 
intensity. Patients with moderate- to- severe sleep disturbance 
reported an average of 1.46 points higher pain intensity than those 
without sleep disturbance in the PPT model. This observation is 
consistent with previous studies implicating a role for sleep distur-
bance in pain perception in healthy subjects as well as patients 
with RA (14,26,34,46). Second, we noted that lower education 
was significantly associated with pain in RA. Jiang et al noted in 
a study of 3,021 DMARD- naive patients with RA that achieving a 
college or university degree was associated with a lower risk of 
reporting higher than median levels of pain at 3, 6, and 12 months 
following initiation of DMARDs (35).
Last, we noted no association between measures of inflam-
mation and our primary outcome of pain intensity. While there was 
a statistically significant association between CRP level and our 
secondary outcome of pain interference, the magnitudes of asso-
ciation were small (mean increase in pain interference T scores 
of 0.08, 0.07, and 0.07 for each unit of CRP in the PPT, TS, and 
CPM models, respectively) and unlikely to be of clinical signifi-
cance because these values were well below the MID. This is con-
sistent with 2 recent studies showing minimal correlation between 
pain and markers of inflammation (CRP level and gray- scale and 
power Doppler ultrasound evaluations) (47,48).
This study has several strengths. The overall sample size is 
larger than that in prior studies of QST and pain in RA. Additionally, 
the study was conducted at 5 different medical centers across the 
US, which makes the results more generalizable to the general RA 
population. This study also studied multiple QST mea sures, includ-
ing extraarticular PPTs, TS, and CPM, while adjusting for important 
potential confounders implicated in pain, including inflammation. 
Strengths of the chosen QST protocol include prior experience with 
its use, a well- established protocol for reference, and similarities to 
other protocols used in RA research allowing for comparisons.
Study limitations include the cross- sectional design, which 
does not permit assessment of causality or directionality of rela-
tionships between QST measures and pain. Another limitation is 
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the heterogeneity of QST assessments across assessors at dif-
ferent sites. To minimize these effects, rigorous training and stan-
dardization methods were employed, resulting in overall ICCs in 
the good to excellent range (19,23). However, reproducibility of the 
CPM measure was notably lower than the other QST measures 
likely due to the complexity of the paradigm, which involves 2 dif-
ferent noxious stimuli and the assessment of 2 PPTs over time. A 
2016 systematic review examined the reliability of CPM among vari-
ous testing conditions (49). ICCs ranged from 0.1 to 0.59 in patients 
with painful conditions, similar to the ICC of 0.45 noted in this study. 
Additionally, simultaneous application of multiple conditioning stim-
uli has been noted to result in lower CPM compared to application 
of a single conditioning stimuli (45). It is possible that this phenom-
enon could interfere with the measurement of CPM in patients with 
existing pain such as that from RA. Further studies should be per-
formed to assess the optimum CPM protocol in patients with RA 
using a variety of conditioning and testing stimuli. Finally, 33 patients 
were excluded from the study due to missing data. These patients 
had lower education and higher levels of anxiety and sleep distur-
bance than the study population, which limited generalizability.
In conclusion, this study has important clinical implications. 
While pain in patients with RA has traditionally been attributed to 
peripheral inflammation, our study suggests that CNS dysregula-
tion of pain enhances pain intensity independent of inflammatory 
activity. In a practice environment where treat- to- target is becoming 
increasingly the standard of care, these results should encourage 
physicians to carefully evaluate the factors contributing to pain in 
patients with active RA prior to changes in treatment with DMARDs. 
Because pain plays an important role in the subjective components 
of many composite measures of disease activity, it is possible that 
patients with centralized pain in the absence of significant inflamma-
tion would have high composite disease activity scores that would 
erroneously prompt a change in the treatment with DMARDs, sub-
jecting the patient to a delay in the appropriate treatment of pain 
as well as to unnecessary exposure to potential DMARD- related 
 toxicities. These findings highlight the need for research into 
the means of identifying pain mechanisms to help guide treatment 
decisions. Further areas of research include longitudinal studies to 
establish the directionality of the relationship between QST meas-
ures and clinical pain assessments, as well as assessment of the 
efficacy of centrally acting agents on controlling pain in RA.
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